Gilead COVID-19 drug gets expanded WHO recommendation


Gilead Sciences Inc. GILD, -0.28% said late Thursday the World Health Organization expanded its recommended guide for the use of the biotech drug maker’s COVID-19 treatment Veklury. In a statement, the company said WHO updated its guidelines to recommend the drug to treat patients with severe COVID, an expansion from simply “those with non-severe COVID-19 at the highest risk of hospitalization.” In late July, European Commission regulators recommended that Veklury be used as an expanded COVID-19 treatment. Veklury

This article was originally published by Read the original article here.

Previous articleEarnings Results: Who doesn’t love bowling? Shares of Bowlero jump after hours as sales beat estimates.
Next articleU.S. stocks finish lower for second time in three days as Treasury yields climb


Please enter your comment!
Please enter your name here